Combination Therapy with Cyclosporine and Methotrexate in Severe Rheumatoid Arthritis
Peter Tugwell, M.D., Theodore Pincus, M.D., David Yocum, M.D., Michael Stein, M.D., Oscar Gluck, M.D., Gunnar Kraag, M.D., Robert McKendry, M.D., John Tesser, M.D., Philip Baker, B.Sc., George Wells, Ph.D., for The Methotrexate–Cyclosporine Combination Study Group
Background Patients with severe rheumatoid arthritis who aretreated with methotrexate frequently have only partial improvement.
Methods In a six-month randomized, double-blind trial, we comparedcombination therapy with cyclosporine (2.5 to 5 mg per kilogramof body weight per day) and methotrexate (at the maximal tolerateddose) with methotrexate and placebo in 148 patients with rheumatoidarthritis who had residual inflammation and disability despitepartial but substantial responses to prior methotrexate treatment.The primary outcome measure was the change in the number oftender joints.
Results As compared with the placebo group, the patients inthe treatment group had a net improvement in the tender-jointcount of 25 percent, or 4.8 joints (95 percent confidence interval,0.7 to 8.9; P = 0.02), and in the swollen-joint count of 25percent, or 3.8 joints (95 percent confidence interval, 1.3to 6.3; P = 0.005); improvement in overall disease activityas assessed by the physician (19 percent, P<0.001) and thepatient (21 percent, P<0.001); and improvement in joint pain(23 percent, P = 0.04) and in the degree of disability (26 percent,P<0.001). Thirty-six patients (48 percent) in the cyclosporinegroup and 12 patients (16 percent) in the placebo group (P<0.001)met the 1993 criteria for improvement of the American Collegeof Rheumatology (more than 20 percent improvement in the numbersof both swollen and tender joints and improvement in three offive other variables). Serum creatinine concentrations increasedby a mean of 0.14±0.27 mg per deciliter (12±24mmol per liter) in the cyclosporine group and by 0.05±0.19mg per deciliter (4±17 mmol per liter) in the placebogroup (P = 0.02).
Conclusions Patients with severe rheumatoid arthritis and onlypartial responses to methotrexate had clinically important improvementafter combination therapy with cyclosporine and methotrexate.Side effects were not substantially increased. Long-term follow-upof patients treated with this combination is needed.
Source Information
From the Department of Medicine and the Clinical Epidemiology Unit, University of Ottawa, Ottawa, Ont., Canada (P.T., G.K., R.M., P.B., G.W.); the Division of Rheumatology and Immunology, Vanderbilt University, Nashville (T.P., M.S.); the Division of Rheumatology and Immunology, University of Arizona, Tucson (D.Y.); and the Arizona Rheumatology Center, Phoenix (O.G., J.T.).
Address reprint requests to Dr. Tugwell at the Department of Medicine, University of Ottawa and Ottawa General Hospital, 501 Smyth Rd., Rm. LM12, Ottawa, ON K1H 8L6, Canada.
Cyclosporine and Methotrexate for Severe Rheumatoid Arthritis
Schlesinger N., Huppert A., Hoch S., Malleson P., Steinberg A. D., Rosh J. R., Birnbaum A. H., van de Rijn M., Kamel O. W., Storb R., Thomas E. D., Tugwell P., Yocum D., Pincus T., Wells G.
Extract |
Full Text
N Engl J Med 1995;
333:1567-1569, Dec 7, 1995.
Correspondence
Etanercept in Rheumatoid Arthritis
Cook D. A., Dimick J. B., Gallagher D. C., Escalante A., del Rincón I., Ferraccioli G.F., Di Poi E., Weinblatt M. E., Burge D. J.
Extract |
Full Text
N Engl J Med 1999;
340:2000-2001, Jun 24, 1999.
Correspondence
This article has been cited by other articles:
Visser, K, Katchamart, W, Loza, E, Martinez-Lopez, J A, Salliot, C, Trudeau, J, Bombardier, C, Carmona, L, van der Heijde, D, Bijlsma, J W J, Boumpas, D T, Canhao, H, Edwards, C J, Hamuryudan, V, Kvien, T K, Leeb, B F, Martin-Mola, E M, Mielants, H, Muller-Ladner, U, Murphy, G, Ostergaard, M, Pereira, I A, Ramos-Remus, C, Valentini, G, Zochling, J, Dougados, M
(2009). Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative. Ann Rheum Dis
68: 1086-1093
[Abstract][Full Text]
Katchamart, W, Trudeau, J, Phumethum, V, Bombardier, C
(2009). Efficacy and toxicity of methotrexate (MTX) monotherapy versus MTX combination therapy with non-biological disease-modifying antirheumatic drugs in rheumatoid arthritis: a systematic review and meta-analysis. Ann Rheum Dis
68: 1105-1112
[Abstract][Full Text]
Isaacs, J. D.
(2008). Therapeutic T-cell manipulation in rheumatoid arthritis: past, present and future. Rheumatology (Oxford)
47: 1461-1468
[Abstract][Full Text]
Bruyn, G A W, Tate, G, Caeiro, F, Maldonado-Cocco, J, Westhovens, R, Tannenbaum, H, Bell, M, Forre, O, Bjorneboe, O, Tak, P P, Abeywickrama, K H, Bernhardt, P, van Riel, P L C, for the RADD study group,
(2008). Everolimus in patients with rheumatoid arthritis receiving concomitant methotrexate: a 3-month, double-blind, randomised, placebo-controlled, parallel-group, proof-of-concept study. Ann Rheum Dis
67: 1090-1095
[Abstract][Full Text]
Saleem, B, Mackie, S, Quinn, M, Nizam, S, Hensor, E, Jarrett, S, Conaghan, P G, Emery, P
(2008). Does the use of tumour necrosis factor antagonist therapy in poor prognosis, undifferentiated arthritis prevent progression to rheumatoid arthritis?. Ann Rheum Dis
67: 1178-1180
[Abstract][Full Text]
Haupl, T., Ostensen, M., Grutzkau, A., Burmester, G.-R., Villiger, P. M.
(2008). Interaction between rheumatoid arthritis and pregnancy: correlation of molecular data with clinical disease activity measures. Rheumatology (Oxford)
47: iii19-iii22
[Abstract][Full Text]
Choy, E H S, Smith, C M, Farewell, V, Walker, D, Hassell, A, Chau, L, Scott, D L, for the CARDERA (Combination Anti-Rheumatic Drugs,
(2008). Factorial randomised controlled trial of glucocorticoids and combination disease modifying drugs in early rheumatoid arthritis. Ann Rheum Dis
67: 656-663
[Abstract][Full Text]
Cohen, J., Calabresi, P., Chakraborty, S., Edwards, K., Eickenhorst, T., Felton, W. III, Fisher, E., Fox, R., Goodman, A., Hara-Cleaver, C., Hutton, G., Imrey, P., Ivancic, D., Mandell, B., Perryman, J., Scott, T., Skaramagas, T., Zhang, H. for the AC
(2008). Avonex Combination Trial in relapsing--remitting MS: rationale, design and baseline data. Mult Scler
14: 370-382
[Abstract]
Aletaha, D, Strand, V, Smolen, J S, Ward, M M
(2008). Treatment-related improvement in physical function varies with duration of rheumatoid arthritis: a pooled analysis of clinical trial results. Ann Rheum Dis
67: 238-243
[Abstract][Full Text]
Guyatt, G. H., Ferrans, C. E., Halyard, M. Y., Revicki, D. A., Symonds, T. L., Varricchio, C. G., Kotzeva, A., Valderas, J. M., Alonso, J. L., Clinical Significance Consensus Meeting Group,
(2007). Exploration of the Value of Health-Related Quality-of-Life Information From Clinical Research and Into Clinical Practice. Mayo Clin Proc.
82: 1229-1239
[Abstract][Full Text]
Goekoop-Ruiterman, Y. P.M., de Vries-Bouwstra, J. K., Allaart, C. F., van Zeben, D., Kerstens, P. J.S.M., Hazes, J. M. W., Zwinderman, A. H., Peeters, A. J., de Jonge-Bok, J. M., Mallee, C., de Beus, W. M., de Sonnaville, P. B.J., Ewals, J. A.P.M., Breedveld, F. C., Dijkmans, B. A.C.
(2007). Comparison of Treatment Strategies in Early Rheumatoid Arthritis: A Randomized Trial. ANN INTERN MED
146: 406-415
[Abstract][Full Text]
Capell, H. A, Madhok, R., Porter, D. R, Munro, R. A L, McInnes, I. B, Hunter, J. A, Steven, M., Zoma, A., Morrison, E., Sambrook, M., Wui Poon, F., Hampson, R., McDonald, F., Tierney, A., Henderson, N., Ford, I.
(2007). Combination therapy with sulfasalazine and methotrexate is more effective than either drug alone in patients with rheumatoid arthritis with a suboptimal response to sulfasalazine: results from the double-blind placebo-controlled MASCOT study. Ann Rheum Dis
66: 235-241
[Abstract][Full Text]
Russell, A S, Wallenstein, G V, Li, T, Martin, M C, Maclean, R, Blaisdell, B, Gajria, K, Cole, J C, Becker, J-C, Emery, P
(2007). Abatacept improves both the physical and mental health of patients with rheumatoid arthritis who have inadequate response to methotrexate treatment. Ann Rheum Dis
66: 189-194
[Abstract][Full Text]
Combe, B, Landewe, R, Lukas, C, Bolosiu, H D, Breedveld, F, Dougados, M, Emery, P, Ferraccioli, G, Hazes, J M W, Klareskog, L, Machold, K, Martin-Mola, E, Nielsen, H, Silman, A, Smolen, J, Yazici, H
(2007). EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis
66: 34-45
[Abstract][Full Text]
Douglas, K M J, Ladoyanni, E, Treharne, G J, Hale, E D, Erb, N, Kitas, G D
(2006). Cutaneous abnormalities in rheumatoid arthritis compared with non-inflammatory rheumatic conditions. Ann Rheum Dis
65: 1341-1345
[Abstract][Full Text]
Yoo, S.-A., Park, B.-H., Park, G.-S., Koh, H.-S., Lee, M.-S., Ryu, S. H., Miyazawa, K., Park, S.-H., Cho, C.-S., Kim, W.-U.
(2006). Calcineurin Is Expressed and Plays a Critical Role in Inflammatory Arthritis. J. Immunol.
177: 2681-2690
[Abstract][Full Text]
Aletaha, D, Ward, M M
(2006). Duration of rheumatoid arthritis influences the degree of functional improvement in clinical trials. Ann Rheum Dis
65: 227-233
[Abstract][Full Text]
Choy, E. H. S., Smith, C., Dore, C. J., Scott, D. L.
(2005). A meta-analysis of the efficacy and toxicity of combining disease-modifying anti-rheumatic drugs in rheumatoid arthritis based on patient withdrawal. Rheumatology (Oxford)
44: 1414-1421
[Abstract][Full Text]
Suresh, E, Lambert, C M
(2005). Combination treatment strategies in early rheumatoid arthritis. Ann Rheum Dis
64: 1252-1256
[Abstract][Full Text]
Waters, V., Sokol, S., Reddy, B., Soong, G., Chun, J., Prince, A.
(2005). The Effect of Cyclosporin A on Airway Cell Proinflammatory Signaling and Pneumonia. Am. J. Respir. Cell Mol. Bio.
33: 138-144
[Abstract][Full Text]
Fraser, A D, van Kuijk, A W R, Westhovens, R, Karim, Z, Wakefield, R, Gerards, A H, Landewe, R, Steinfeld, S D, Emery, P, Dijkmans, B A C, Veale, D J
(2005). A randomised, double blind, placebo controlled, multicentre trial of combination therapy with methotrexate plus ciclosporin in patients with active psoriatic arthritis. Ann Rheum Dis
64: 859-864
[Abstract][Full Text]
Dougados, M, Emery, P, Lemmel, E M, Zerbini, C A F, Brin, S, van Riel, P
(2005). When a DMARD fails, should patients switch to sulfasalazine or add sulfasalazine to continuing leflunomide?. Ann Rheum Dis
64: 44-51
[Abstract][Full Text]
Lee, S J, Kavanaugh, A
(2004). A need for greater reporting of socioeconomic status and race in clinical trials. Ann Rheum Dis
63: 1700-1701
[Full Text]
Choy, E. H.
(2004). Two is better than one? Combination therapy in rheumatoid arthritis. Rheumatology (Oxford)
43: 1205-1207
[Full Text]
Fiehn, C., Muller-Ladner, U., Gay, S., Krienke, S., Freudenberg-Konrad, S., Funk, J., Ho, A. D., Sinn, H., Wunder, A.
(2004). Albumin-coupled methotrexate (MTX-HSA) is a new anti-arthritic drug which acts synergistically to MTX. Rheumatology (Oxford)
43: 1097-1105
[Abstract][Full Text]
Yocum, D. E., Furst, D. E., Bensen, W. G., Burch, F. X., Borton, M. A., Mengle-Gaw, L. J., Schwartz, B. D., Wisememandle, W., Mekki, Q. A.
(2004). Safety of tacrolimus in patients with rheumatoid arthritis: long-term experience. Rheumatology (Oxford)
43: 992-999
[Abstract][Full Text]
O'Dell, J. R.
(2004). Therapeutic Strategies for Rheumatoid Arthritis. NEJM
350: 2591-2602
[Full Text]
Strand, V., Cohen, S., Crawford, B., Smolen, J. S., Scott, D. L.
(2004). Patient-reported outcomes better discriminate active treatment from placebo in randomized controlled trials in rheumatoid arthritis. Rheumatology (Oxford)
43: 640-647
[Abstract][Full Text]
Brennan, A., Bansback, N., Reynolds, A., Conway, P.
(2004). Modelling the cost-effectiveness of etanercept in adults with rheumatoid arthritis in the UK. Rheumatology (Oxford)
43: 62-72
[Abstract][Full Text]
Marchesoni, A., Battafarano, N., Arreghini, M., Panni, B., Gallazzi, M., Tosi, S.
(2003). Radiographic progression in early rheumatoid arthritis: a 12-month randomized controlled study comparing the combination of cyclosporin and methotrexate with methotrexate alone. Rheumatology (Oxford)
42: 1545-1549
[Abstract][Full Text]
Gerards, A H, Landewe, R B M, Prins, A P A, Bruijn, G A W, Goei The, H S, Laan, R F J M, Dijkmans, B A C
(2003). Cyclosporin A monotherapy versus cyclosporin A and methotrexate combination therapy in patients with early rheumatoid arthritis: a double blind randomised placebo controlled trial. Ann Rheum Dis
62: 291-296
[Abstract][Full Text]
Osiri, M, Suarez-Almazor, M E, Wells, G A, Robinson, V, Tugwell, P
(2003). Number needed to treat (NNT): implication in rheumatology clinical practice. Ann Rheum Dis
62: 316-321
[Abstract][Full Text]
Gause, A.
(2003). Progress in the treatment of rheumatic disease. Nephrol Dial Transplant
18: 13-16
[Full Text]
Morgan, C, Lunt, M, Brightwell, H, Bradburn, P, Fallow, W, Lay, M, Silman, A, Bruce, I N
(2003). Contribution of patient related differences to multidrug resistance in rheumatoid arthritis. Ann Rheum Dis
62: 15-19
[Abstract][Full Text]
Isnard Bagnis, C., Tezenas du Montcel, S., Beaufils, H., Jouanneau, C., Jaudon, M. C., Maksud, P., Mallet, A., LeHoang, P., Deray, G.
(2002). Long-Term Renal Effects of Low-Dose Cyclosporine in Uveitis-Treated Patients: Follow-Up Study. J. Am. Soc. Nephrol.
13: 2962-2968
[Abstract][Full Text]
Kremer, J. M., Genovese, M. C., Cannon, G. W., Caldwell, J. R., Cush, J. J., Furst, D. E., Luggen, M. E., Keystone, E., Weisman, M. H., Bensen, W. M., Kaine, J. L., Ruderman, E. M., Coleman, P., Curtis, D. L., Kopp, E. J., Kantor, S. M., Waltuck, J., Lindsley, H. B., Markenson, J. A., Strand, V., Crawford, B., Fernando, I., Simpson, K., Bathon, J. M.
(2002). Concomitant Leflunomide Therapy in Patients with Active Rheumatoid Arthritis despite Stable Doses of Methotrexate: A Randomized, Double-Blind, Placebo-Controlled Trial. ANN INTERN MED
137: 726-733
[Abstract][Full Text]
Temekonidis, T I, Georgiadis, A N, Alamanos, Y, Bougias, D V, Voulgari, P V, Drosos, A A
(2002). Infliximab treatment in combination with cyclosporin A in patients with severe refractory rheumatoid arthritis. Ann Rheum Dis
61: 822-825
[Abstract][Full Text]
Ferraccioli, G. F., Gremese, E., Tomietto, P., Favret, G., Damato, R., Di Poi, E.
(2002). Analysis of improvements, full responses, remission and toxicity in rheumatoid patients treated with step-up combination therapy (methotrexate, cyclosporin A, sulphasalazine) or monotherapy for three years. Rheumatology (Oxford)
41: 892-898
[Abstract][Full Text]
Scott, D. L., Strand, V.
(2002). The effects of disease-modifying anti-rheumatic drugs on the Health Assessment Questionnaire score. Lessons from the leflunomide clinical trials database. Rheumatology (Oxford)
41: 899-909
[Abstract][Full Text]
Kvien, T K, Zeidler, H K, Hannonen, P, Wollheim, F A, Forre, O, Hafstrom, I, Kaltwasser, J P, Leirisalo-Repo, M, Manger, B, Laasonen, L, Prestele, H, Kurki, P
(2002). Long term efficacy and safety of cyclosporin versus parenteral gold in early rheumatoid arthritis: a three year study of radiographic progression, renal function, and arterial hypertension. Ann Rheum Dis
61: 511-516
[Abstract][Full Text]
Machein, U., Buss, B., Spiller, I., Braun, J., Rudwaleit, M., Faerber, L., Sieper, J.
(2002). Effective treatment of early rheumatoid arthritis with a combination of methotrexate, prednisolone and cyclosporin. Rheumatology (Oxford)
41: 110-111
[Full Text]
Pisetsky, D. S., St.Clair, E. W.
(2001). Progress in the Treatment of Rheumatoid Arthritis. JAMA
286: 2787-2790
[Full Text]
Hochberg, M C, Tracy, J K, Flores, R H
(2001). ""Stepping-up"" from methotrexate: a systematic review of randomised placebo controlled trials in patients with rheumatoid arthritis with an incomplete response to methotrexate. Ann Rheum Dis
60: iii51-54
[Full Text]
Kim, W-U, Seo, Y-I, Park, S-H, Lee, W-K, Lee, S-K, Paek, S-I, Cho, C-S, Song, H-H, Kim, H-Y
(2001). Treatment with cyclosporin switching to hydroxychloroquine in patients with rheumatoid arthritis. Ann Rheum Dis
60: 514-517
[Abstract][Full Text]
Kremer, J. M.
(2001). Rational Use of New and Existing Disease-Modifying Agents in Rheumatoid Arthritis. ANN INTERN MED
134: 695-706
[Abstract][Full Text]
Griffiths, B, Emery, P
(2001). The treatment of lupus with cyclosporin A. Lupus
10: 165-170
[Abstract]
Verhoeven, A C, Boers, M, van der Linden, S
(2000). Responsiveness of the core set, response criteria, and utilities in early rheumatoid arthritis. Ann Rheum Dis
59: 966-974
[Abstract][Full Text]
Feldmann, M., Miotla, J., Paleolog, E., Williams, R., Malfait, A.-M., Taylor, P., Brennan, F. M, Maini, R. N
(2000). Future prospects for anti-cytokine treatment. Ann Rheum Dis
59: i119-122
[Abstract][Full Text]
Smolen, J. S., Graninger, W. B., Emery, P.
(2000). Leflunomide, a new disease-modifying anti-rheumatic drug and the never ending rheumatoid arthritis story. Rheumatology (Oxford)
39: 689-692
[Full Text]
Bingham, S., Emery, P.
(2000). Resistant rheumatoid arthritis clinics-- a necessary development?. Rheumatology (Oxford)
39: 2-5
[Full Text]
Pincus, T., O'Dell, J. R., Kremer, J. M.
(1999). Combination Therapy with Multiple Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis: A Preventive Strategy. ANN INTERN MED
131: 768-774
[Abstract][Full Text]
Hurst, N. P.
(1999). Combination therapy in rheumatoid arthritis. Rheumatology (Oxford)
38: 789-789
[Full Text]
Cook, D. A., Dimick, J. B., Gallagher, D. C., Escalante, A., del Rincon, I., Ferraccioli, G.F., Di Poi, E., Weinblatt, M. E., Burge, D. J.
(1999). Etanercept in Rheumatoid Arthritis. NEJM
340: 2000-2001
[Full Text]
Veale, D J, Reece, R J, Parsons, W, Radjenovic, A, O'Connor, P J, Orgles, C S, Berry, E, Ridgway, J P, Mason, U, Boylston, A W, Gibbon, W, Emery, P
(1999). Intra-articular primatised anti-CD4: efficacy in resistant rheumatoid knees. A study of combined arthroscopy, magnetic resonance imaging, and histology. Ann Rheum Dis
58: 342-349
[Abstract][Full Text]
Dougados, M., Combe, B., Cantagrel, A., Goupille, P., Olive, P., Schattenkirchner, M., Meusser, S, Paimela, L, Rau, R., Zeidler, H., Leirisalo-Repo, M., Peldan, K.
(1999). Combination therapy in early rheumatoid arthritis: a randomised, controlled, double blind 52 week clinical trial of sulphasalazine and methotrexate compared with the single components. Ann Rheum Dis
58: 220-225
[Abstract][Full Text]
Weinblatt, M. E., Kremer, J. M., Bankhurst, A. D., Bulpitt, K. J., Fleischmann, R. M., Fox, R. I., Jackson, C. G., Lange, M., Burge, D. J.
(1999). A Trial of Etanercept, a Recombinant Tumor Necrosis Factor Receptor:Fc Fusion Protein, in Patients with Rheumatoid Arthritis Receiving Methotrexate. NEJM
340: 253-259
[Abstract][Full Text]
Guyatt, G. H., Naylor, C. D., Juniper, E., Heyland, D. K., Jaeschke, R., Cook, D. J.
(1997). Users' Guides to the Medical Literature: XII. How to Use Articles About Health-Related Quality of Life. JAMA
277: 1232-1237
[Abstract]
Schlesinger, N., Huppert, A., Hoch, S., Malleson, P., Steinberg, A. D., Rosh, J. R., Birnbaum, A. H., van de Rijn, M., Kamel, O. W., Storb, R., Thomas, E. D., Tugwell, P., Yocum, D., Pincus, T., Wells, G.
(1995). Cyclosporine and Methotrexate for Severe Rheumatoid Arthritis. NEJM
333: 1567-1569
[Full Text]
(1995). Cyclosporine and Corticosteroids for Rheumatoid Arthritis. Journal Watch Dermatology
1995: 18-18
[Full Text]
(1995). CYCLOSPORINE AND CORTICOSTEROIDS FOR RHEUMATOID ARTHRITIS. JWatch General
1995: 1-1
[Full Text]
Breedveld, F. C.
(1995). New Perspectives on Treating Rheumatoid Arthritis. NEJM
333: 183-184
[Full Text]
